Related Experiment Video

Updated: Dec 15, 2025

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.2K

Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept

Huan Liu1,2, Yue Ma1, Hong-Chang Xu1

  • 1Division of Ocular Injuries, Department of Ophthalmology, The Third Affiliated Hospital of Hebei Medical University , Shijiazhuang, Hebei, China.

Current Eye Research
|July 8, 2020
PubMed

Insights

Conbercept is a new anti-vascular endothelial growth factor (VEGF) therapy for ocular vasculopathies. Further research is needed to confirm its long-term safety and efficacy compared to other anti-VEGF drugs.

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Pharmacology

Background:

  • Ocular vasculopathies contribute significantly to vision impairment and blindness.
  • Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis and neovascularization.
  • Anti-VEGF therapies are established treatments for neovascular retinal diseases.

Purpose of the Study:

  • To review the therapeutic efficacy of conbercept for ocular vasculopathies.
  • To compare conbercept with other anti-VEGF agents.

Main Methods:

  • A comprehensive literature search was conducted across multiple electronic databases.
  • Review of existing studies on conbercept and other anti-VEGF therapies.

Main Results:

  • Conbercept is a recent anti-VEGF drug approved in China for ocular vascular disorders.
  • Bevacizumab is the most recent anti-VEGF agent approved in the USA and Europe.
  • Limited clinical trials have directly compared conbercept with other anti-VEGF drugs.

Conclusions:

  • Conbercept offers an additional anti-VEGF treatment option for neovascular age-related macular degeneration (AMD) and other retinal vascular conditions.
  • Large-scale, randomized clinical trials are necessary to evaluate conbercept's long-term safety, efficacy, and comparative advantages.

Keywords:
Age-related macular degenerationbranch retinal vein occlusionconberceptcorneal neovascularizationdiabetic retinopathymyopic choroidal neovascularizationneovascular glaucomapolypoidal choroidal vasculopathyvascular endothelial growth factor

More Related Videos

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

9.7K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
870
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
328
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
279
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
352